Mazdutide vs MK-677
Extensively Studied vs Well Studied
monitor Mechanism-based · 47% Both Mazdutide and MK-677 affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
Mazdutide MK-677
Weight 4,563.1 Da 624.77 Da
Half-life 6-8 days ~24 hours
Chain 33 amino acids —
Type Oxyntomodulin analog with fatty acid conjugation Non-peptide ghrelin receptor agonist
Key Benefits
Mazdutide
01 Up to 20% body weight loss
02 Superior glycemic control versus semaglutide
03 Increased energy expenditure via glucagon receptor activation
04 Improved cardiometabolic markers (BP, lipids, liver fat)
05 Once-weekly injection convenience
MK-677
01 97% increase in 24-hour growth hormone secretion
02 40-72% elevation in IGF-1 levels
03 Enhanced sleep quality with improved REM patterns
04 Preferential lean tissue gains of 1.1-2.7kg over 8-12 months
05 15% basal metabolic rate increase within 2 weeks
06 Oral administration (no injections required)
Dosing Protocols
Mazdutide
Start 1.5-3mg weekly, titrate up to 6-9mg based on response / Once weekly injection
Weight loss initiation (3mg target) 1.5mg → 3mg Once weekly
Weight loss progression (4.5mg target) 1.5mg → 3mg → 4.5mg Once weekly
Weight loss optimization (6mg target) 2mg → 4mg → 6mg Once weekly
Maximum weight loss (9mg target) 3mg → 6mg → 9mg Once weekly
T2D management (mild-moderate) 3-4.5mg weekly Once weekly
MK-677
Start 12.5mg daily, increase to 25mg based on tolerance / Once daily, preferably at bedtime on empty stomach
Side Effects
Mazdutide
Nausea (mild-moderate, typically improves over time)
Diarrhea
Vomiting
Increased heart rate (5-17 bpm observed)
MK-677
Appetite stimulation (>50% of users)
Water retention (30-40%)
Lethargy (20-30%)
Fasting glucose elevation (5-15mg/dL)
Note on testosterone suppression: at doses up to 20 mg daily, MK-677 is unlikely to cause significant testosterone suppression on its own. Above 20 mg daily, the likelihood of suppression and other side effects (insulin resistance, water retention, lethargy) increases. The case report documenting 85.7% testosterone suppression involved co-administration with LGD-4033, a SARM known to be profoundly suppressive, making the SARM the likely primary driver of that suppression.
Contraindications
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome history (class warning for GLP-1 agonists)
Pregnancy or breastfeeding (insufficient safety data)
Heart disease or congestive heart failure
Diabetes or pre-diabetes
Active cancer
Severe cardiovascular disease
Pregnancy or breastfeeding
Research Evidence
Mazdutide MK-677
Status Extensively Studied Well Studied
References 4 studies 7 studies
Latest — July 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.